Corvus Pharmaceuticals Inc’s recent filing unveils that its President and CEO MILLER RICHARD A MD acquired Company’s shares for reported $1.0 million on May 06 ’24. In the deal valued at $1.73 per share,577,634 shares were bought. As a result of this transaction, MILLER RICHARD A MD now holds 577,634 shares worth roughly $1.72 million.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Then, Jones William Benton bought 20,000 shares, generating $34,624 in total proceeds. Upon buying the shares at $1.73, the insider now owns 153,773 shares.
Oppenheimer initiated its Corvus Pharmaceuticals Inc [CRVS] rating to an Outperform in a research note published on August 18, 2023; the price target was $7. Cantor Fitzgerald began covering CRVS with “an Overweight” recommendation on May 27, 2021. Mizuho revised its rating on February 10, 2021. It rated CRVS as “a Neutral” which previously was an “a Buy”.
Price Performance Review of CRVS
On Friday, Corvus Pharmaceuticals Inc [NASDAQ:CRVS] saw its stock fall -0.33% to $2.98. Over the last five days, the stock has gained 15.50%. Corvus Pharmaceuticals Inc shares have risen nearly 69.32% since the year began. Nevertheless, the stocks have risen 37.33% over the past one year. While a 52-week high of $3.00 was reached on 08/02/24, a 52-week low of $1.05 was recorded on 04/18/24. SMA at 50 days reached $2.11, while 200 days put it at $1.87. A total of 0.51 million shares were traded, compared to the trading of 0.72 million shares in the previous session.
Levels Of Support And Resistance For CRVS Stock
The 24-hour chart illustrates a support level at 2.84, which if violated will result in even more drops to 2.69. On the upside, there is a resistance level at 3.14. A further resistance level may holdings at 3.29. The Relative Strength Index (RSI) on the 14-day chart is 71.06, which indicates overbought technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at 0.40, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bullish at 14.78%. Stochastics%K at 80.97% indicates the stock is a selling.
The most recent change occurred on September 12, 2019 when Mizuho began covering the stock and recommended ‘”a Buy”‘ rating .
